15:03 , Mar 1, 2018 |  BC Innovations  |  Translation in Brief

A path less traveled

A team from PSL Research University has shown how a nitric oxide (NO)-donating compound steers TNFα signaling away from a pro-survival pathway towards one that promotes death in cancer cells. The findings suggest NO-donors could...
00:51 , Mar 29, 2017 |  BC Innovations  |  Distillery Therapeutics

Hepatic

INDICATION: Non-alcoholic steatohepatitis (NASH) Patient sample, mouse and non-human primate (NHP) studies suggest CFLAR or its mimics could help treat NASH. In liver tissue samples, levels of CFLAR were lower in patients than in healthy volunteers,...
23:41 , Feb 21, 2017 |  BC Extra  |  Clinical News

Chinese scientists identify NASH target

Researchers in China identified CASP8 and FADD like apoptosis regulator (CFLAR; c-FLIP) as a new target for non-alcoholic steatohepatitis (NASH) that could suppress the disease and related metabolic disorders. The study was published in Nature...
07:00 , Jun 29, 2015 |  BC Week In Review  |  Company News

Cardiff University, Tiziana Life Sciences deal

The university granted Tiziana exclusive, worldwide rights to small molecule OH14. Tiziana plans to develop the preclinical cellular FLICE-like inhibitory protein (c-FLIP) inhibitor for cancer. The company plans to start clinical testing of...
07:00 , Aug 21, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Ophthalmic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Ophthalmic disease Glaucoma Caspase-8 (CASP8; FLICE); toll-like receptor 4 (TLR4) Rodent studies suggest inhibiting CASP8 could help treat...
07:00 , Apr 3, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Acute promyelocytic leukemia (APL) Retinoic acid receptor-α (RARA); promyelocytic leukemia (PML); histone deacetylase (HDAC) Cell culture studies...
07:00 , Jun 10, 2013 |  BioCentury  |  Emerging Company Profile

ONL Therapeutics: Eyeing Fas

ONL Therapeutics LLC is developing a peptide antagonist of Fas-mediated apoptosis that could become the first pharmacotherapy to prevent vision loss associated with non-exudative retinal detachment. The company expects its products would be used as...
08:00 , Jan 21, 2013 |  BioCentury  |  Emerging Company Profile

Oncorena: Metastatic destruction

Oncorena AB is banking on the specificity of orellanine for killing kidney cells anywhere in the body to prolong survival in patients with metastatic renal cell carcinoma. But the probable side effects mean the company...
07:00 , Jun 28, 2012 |  BC Innovations  |  Targets & Mechanisms

Fragmentary progress in endometriosis

A team from the Baylor College of Medicine has treated endometriosis in mice by blocking a pathway that produces a fragment of nuclear receptor coactivator 1 in endometrial tissue.1 Now, small molecule inhibitors are needed...
07:00 , Jun 14, 2012 |  BC Innovations  |  Cover Story

Crafting cancer combinations

Two U.S. groups have developed platforms that could improve the identification of cancer drug combinations that address drug resistance. A team from The University of North Carolina at Chapel Hill School of Medicine is using...